Verve's top drug, Verve-102, is designed to target a gene called PCSK9, which is associated with heart health and cholesterol levels.

Accenture PLC (ACN) is expected to report $3.32 for 3Q. CarMax Inc (KMX) is expected to report $1.19 for 1Q. Coffee Holding Co Inc (JVA) is expected to report $0.06 for 2Q. Darden Restaurants Inc (DRI ...

The National Institutes of Health is undertaking an extended study of the health effects that East Palestine, Ohio, residents ...

Eli Lilly (NYSE:LLY) announced it would appeal a decision by the U.K. health authorities not to recommend the company’s new ...